Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)DiseaseChronic Neutrophil LeukemiaSubgroupICD10D47.1MeSHLeukemia, Neutrophilic, ChronicSequenceChemotherapyChemo-substanceRuxolitinibChemo-substanceRuxolitinibChemo-substanceRuxolitinibChemo-substanceRuxolitinibNo. Substances1 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentiondisease controlRisksAnemia Hb below 8g/dlBleedingEmetogenicity (MASCC/ESMO)Heart FailureInfectionsLymphopeniaPainPneumoniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorDao KTDiseasechronische NeutrophilenleukämieOriginKnight Cancer Institute, Oregon Health and Science University, Portland, USAProtocols in Revision 1 protocol foundProtocols under revision.Ruxolitinib 15, Chronic Neutrophil Leukemia (PID804 V1.0)
